Hugo Vance: You looked slightly unsettled when you walked in — more so than usual.
Lila Soto: I've been sitting with something that I genuinely cannot resolve, and I wanted to see if you could. There's a category of placebo trial — they're called open-label — where the patient is told, explicitly, 'what you are taking has no active ingredient.' Full disclosure. And their symptoms still improve. Pain goes down. Measurably.
Lila Soto: And that shouldn't — I mean, everything I thought I understood about why placebos work rested on the patient not knowing. The whole architecture of it. Henry Beecher in the fifties, the foundational research on post-surgical pain and patient belief — that work was built on the assumption that the effect needed the illusion intact.
Hugo Vance: Now, here's where I'd be cautious about how we frame Beecher. His contribution was legitimizing the effect scientifically — insisting it was real physiology, not imagination. But you're right that deception was baked into his model as a precondition. The open-label finding doesn't just refine that — it removes the precondition entirely.
Lila Soto: Which means... what's left? If not deception, what is the engine?
Hugo Vance: Expectation. Anticipatory belief that relief is coming initiates genuine biological change — that is the thesis, and it is not a soft one. The neuroimaging has made it visible. Brain regions implicated in pain processing show measurably reduced activity. This is neuroscience now, not just reported experience.
Lila Soto: Mm, and Beecher's own number — thirty-five percent of post-surgical patients getting real pain relief from placebo — that held even then, before anyone could image a brain during the response.
Hugo Vance: Held then. Holds now. Seventy years of refining the mechanism, and the effect size has not budged. That is the strange, still center of all this.
Lila Soto: So what we're really trying to figure out today is — if expectation is the drug, what are the conditions that activate it? Because transparency apparently doesn't turn it off.
Hugo Vance: That is, I think, the right way to put it.
Lila Soto: But if expectation is the condition that activates it — I mean, how does that actually become a physical thing? Like, what is happening in the body?
Hugo Vance: Think of it this way. When your brain decides relief is coming, it starts filling its own prescription. Before anything touches you. It releases endorphins — the body's own opioids — through the same pathways a morphine tablet would use. The drug and the belief arrive at the same destination by the same road.
Lila Soto: The brain just... manufactures the medication.
Hugo Vance: Manufactures it. Yes. Now, the endogenous opioid system is not metaphor — it is a physical release event. The question is whether we actually see it, or whether we're just trusting patient reports.
Lila Soto: Which is the part I don't fully trust yet. How do we know it's not just someone saying they feel better?
Hugo Vance: And that was the standing objection for decades. Then neuroimaging answered it directly. fMRI and PET scans, watching the brain during placebo analgesia — the anterior cingulate cortex, which is central to pain processing, shows measurably reduced activity. The periaqueductal gray, the midbrain hub that gates pain signals downward through endorphin release, goes quiet. We are watching the mechanism switch on.
Lila Soto: Wait — you can see the periaqueductal gray actually changing during a sugar pill response?
Hugo Vance: You can. That is what converted this from anecdote to neuroscience. The imaging is direct visual evidence — not inference, not self-report.
Lila Soto: Okay but — and I keep wondering about this — that's still just pain. Endorphins, pain pathways. Is that the whole system, or is something else running underneath it too?
Hugo Vance: I think this is genuinely startling. Raúl de la Fuente-Fernández ran studies on Parkinson's patients — and placebo triggered measurable dopamine release in the striatum. That is a completely separate neurotransmitter system. Motor circuits, reward circuits. Pain wasn't even the variable.
Lila Soto: The striatum lighting up from expectation alone.
Hugo Vance: Which means — and I want to be precise here — expectation isn't operating through one lever. Endorphins for pain, dopamine for motor and reward. The brain is running, well, parallel pharmacology. The mechanism doesn't respect the categories we built our drug trials around.
Lila Soto: And that's what makes the OPRM1 A118G finding so strange to sit with — because if the system is that broad, the fact that some people's opioid receptors are just genetically shaped differently means the same expectation lands on completely different biological hardware.
Hugo Vance: Yes — and that's the seam I want to pry open, because the OPRM1 finding almost lets us dodge the harder question. The hardware variation is real, but it doesn't explain why the mechanism runs *at all* when you've told the patient the pill is inert. Expectation alone shouldn't survive full transparency, by any simple model. And yet.
Lila Soto: That's the part I can't quite land. If I *know* it's sugar, what is my brain expecting?
Hugo Vance: Conditioning. Pavlovian conditioning — and I mean that precisely, not loosely. The nervous system has learned. Every prior time that person swallowed a pill in a clinical setting and felt relief, the cues got encoded: the white coat, the ritual of the capsule, the room itself. Those become the stimulus. The pharmacology was just the unconditioned trigger that built the reflex in the first place.
Lila Soto: Oh — so the room is doing it. Not the belief about *this* pill.
Hugo Vance: The room, the smell, the exchange with the doctor. All of it. And crucially — this runs below conscious deliberation. A patient can hold the thought 'I know this is inert' and the nervous system still fires the conditioned analgesic response, because those are separate systems. One is propositional. The other is, well, older.
Lila Soto: That's kind of alarming, actually. You can't think your way out of it.
Hugo Vance: Which brings me to a scenario I find clarifying. Tuesday morning, 9:47. A woman sits across from her rheumatologist — same drug, same dose as last month. Identical prescription. But today the doctor is rushed. Uncertain. The therapeutic context has fractured. And her outcome measurably differs. Not because the molecule changed. Because the conditioned cues changed.
Lila Soto: The amygdala is reading the doctor's body language.
Hugo Vance: Almost certainly. The amygdala feeds into pain processing and catecholamine release — it is not a passive observer of the clinical encounter. It is a participant.
Lila Soto: And if the mechanism is conditioning, then open-label placebos aren't paradoxical at all. You're not asking the patient to believe in the sugar pill. You're activating a reflex they built over years of actual treatment. The deception was never the point. The *history* was.
Hugo Vance: Which means — and I think this is genuinely significant — you can engage this honestly. You tell the patient exactly what is happening. The conditioning pathway doesn't require the lie. That opens clinical possibilities that medicine has been too uncomfortable to take seriously.
Lila Soto: Yeah — though I want to flag something we haven't touched yet, because I think it makes all of this considerably more complicated. The same expectation system that builds the analgesic reflex can run in reverse. And what that means for how we practice informed consent — that's where I think this gets genuinely difficult.
Hugo Vance: Indeed. And I'd rather we don't rush past that.
Lila Soto: The reverse of it bothers me. Because if positive expectation releases endorphins and lights up dopamine, the mirror — negative expectation — actually deactivates dopamine and activates cholecystokinin. That's not a soft psychological complaint. That's a measurable neurochemical event moving in the wrong direction.
Hugo Vance: Cholecystokinin. Yes. The nocebo effect has a mechanism — it is not just 'feeling worse because you're worried.' The system is bidirectional at the neurotransmitter level.
Lila Soto: And that's what makes informed consent — I mean, the way we actually do it — feel suddenly very strange to me.
Hugo Vance: Strange in what direction?
Lila Soto: If a clinician reads a patient the full side-effect list — every risk, every probability — and the expectation system is this bidirectional and this literal... that's a biological intervention. You're not just informing them. You're potentially activating nocebo pathways. Iatrogenically. With your words.
Hugo Vance: Well. That is the bind, isn't it. Full informed consent is a legal and moral obligation. But detailed negative priming can worsen outcomes through the same mechanism — in reverse — that makes context therapeutic. We've built the ethics of medicine on one principle, and the neuroscience of medicine on another, and they are now pulling against each other.
Lila Soto: Hold on — are we actually saying informed consent might be iatrogenic?
Hugo Vance: I'm saying it can be. Not that it is, categorically — I want to be precise. The question is whether how you deliver that information changes the neurobiological outcome. And I think the answer is yes, which means the content of consent and the delivery of consent are clinically different variables. We treat them as one.
Lila Soto: And this is where the OPRM1 A118G finding gets uncomfortable again — because if the nocebo response runs through the same expectation machinery as the placebo response, and some people's opioid receptors are just shaped differently genetically, then the same doctor reading the same risk list is harming some patients more than others. Without knowing which ones.
Hugo Vance: Without any diagnostic tool to tell you. Context isn't universally prescribable — I said that earlier — but it also isn't uniformly toxic. The OPRM1 A118G polymorphism cuts both ways. The same genetic variation that limits placebo analgesia in some patients may also limit nocebo harm. We don't have the clinical data to say.
Lila Soto: Mm — so we can't even personalize our way out of it yet.
Hugo Vance: No. And that brings me back to Beecher's number — because I find it genuinely haunting in this context. Thirty-five percent of post-surgical patients getting real pain relief from placebo, 1950s data. Seventy years later, the mechanism is exquisitely mapped — endorphins, dopamine, the anterior cingulate cortex going quiet, cholecystokinin running the nocebo in reverse. The neuroscience is beautiful. The effect size has not moved. Which means understanding the mechanism has not made us better at deploying it. Or avoiding its mirror.
Lila Soto: That's — yeah. We know exactly what the system is doing, and we still can't turn the dial.
Hugo Vance: Which is, I think, the most honest thing we can say about where the therapeutic alliance sits right now. The patient-clinician relationship is a measurable clinical variable — it activates the same neural pathways the placebo response uses — and yet we have no training curriculum for managing it, no protocol for nocebo risk during consent. The mechanism is understood. The institution hasn't moved.
Lila Soto: What I can't settle — and maybe this is where we just have to stop — is the training question. If clinician behavior is a therapeutic variable, if your tone and your confidence are running the endogenous pain modulation system in the patient's nervous system whether you know it or not... what happens when you try to standardize it? Like, you audit the doctor's handshake. You script the confident delivery. Does the conditioning pathway care that it's performed?
Hugo Vance: You see, that is — I've been sitting with exactly that, and I don't have a clean answer. The therapeutic alliance activates the same neural architecture the placebo response uses. That's the finding. But the architecture presumably can't distinguish authentic warmth from rehearsed warmth. The periaqueductal gray doesn't audit intention.
Lila Soto: And yet something feels like it would be lost.
Hugo Vance: Yes. And I'm genuinely not sure whether that feeling survives scrutiny or whether it's just, well — professional sentiment protecting its own territory. Medicine has spent two centuries organizing itself around the active ingredient. The mechanism we've been describing has been running underneath every prescription, every clinical encounter, the entire time. Unnamed. Untrained for. The institution looked away. And now — I mean, what does it look like if it actually takes this seriously? I can't picture it, and that's not a comfortable thing to admit.
Lila Soto: I can't either. And I think that's — I mean, that might just be where we are. The neuroscience is there. The imaging is there. Beecher's thirty-five percent is still thirty-five percent. And we're sitting here genuinely not knowing what to do with it at the institutional level.
Lila Soto: Thank you for not trying to resolve it.
